[Matrix metalloproteinases and hypertrophic cardiomyopathy]

Kardiologiia. 2014;54(5):4-7. doi: 10.18565/cardio.2014.5.4-7.
[Article in Russian]

Abstract

Prognosis of patients with hypertrophic cardiomyopathy (HCMP) to a great extent is determined by clinical variant of the disease. As the system of matrix metalloproteinases (MMPs) plays an important role in development and progression of the processes of fibroformation and tissue remodeling polymorphisms of modifier genes regulating its components can influence clinical course of HCMP. Among possible markers of prognostication of the course of cardiovascular diseases the role of MMPs and their tissue inhibitors has been discussed. With the aim of studying effects of MMPs on the course of HCMP we conducted this investigation in which we included 58 patients and a group of healthy volunteers (control group) with comparable sex and age. In all participants (n=112) we determined polymorphism of MMP-3 - rs3025058 and markers of fibroformation (MMP-3, TIMP-1, TIMP-2, and collagen IV). We found that unfavorable allele variant MMP-3 1171 was associated with hypertrophy of interventricular septum. We also established that levels of TIMP-1 in the group of patients with HCMP were significantly lowered in comparison with those in control group. Concentration of marker MMP-3 was elevated in the group of patients with variant "atrial fibrillation" compared with groups of stable course and progressing course. We revealed medium degree reverse correlation between MMP-3 marker and thickness of left ventricular posterior wall and direct correlation of this parameter with coefficient of asymmetry. Polymorphism MMP-3 - 1171 produced an impact on the level of TIMP-1 marker. The data obtained by us confirm effect of the system of MMPs on formation of hypertrophic remodeling of the heart in HCMP.

Publication types

  • English Abstract

MeSH terms

  • Adult
  • Atrial Fibrillation* / etiology
  • Atrial Fibrillation* / genetics
  • Atrial Fibrillation* / physiopathology
  • Biomarkers / metabolism
  • Cardiomyopathy, Hypertrophic* / complications
  • Cardiomyopathy, Hypertrophic* / diagnosis
  • Cardiomyopathy, Hypertrophic* / genetics
  • Cardiomyopathy, Hypertrophic* / physiopathology
  • Female
  • Heart Ventricles / metabolism
  • Heart Ventricles / pathology
  • Heart Ventricles / physiopathology
  • Humans
  • Male
  • Matrix Metalloproteinase 3 / genetics*
  • Middle Aged
  • Polymorphism, Genetic
  • Prognosis
  • Statistics as Topic
  • Ventricular Remodeling / genetics*

Substances

  • Biomarkers
  • Matrix Metalloproteinase 3